Read More Pharma Industry News Rznomics gets FDA RMAT status for RZ-001, but can one liver cancer signal carry a platform story? RNA editing has a regulatory opening in liver cancer. Rznomics now must prove RZ-001 can turn FDA momentum into durable clinical value. bySrinathMay 9, 2026